AbCellera Biologics

Traded on the St. Petersburg Stock Exchange
AbCellera Biologics is a Canadian high-tech company that created an innovative platform for the analysis and identification of antibodies based on artificial intelligence technology. AbCellera Biologics was founded in 2012 and its headquarters are located in Vancouver, Canada.
AbCellera Biologics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

AbCellera Biologics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

AbCellera Biologics cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

AbCellera Biologics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

AbCellera Biologics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
AbCellera Biologics assets
AbCellera Biologics cash flows

AbCellera Biologics dividend policy

The company doesn't provide dividend

AbCellera Biologics shares

TickerNameTypeNominal valueISINPrice
ABCL:USAbCellera BiologicsCommon share-CA00288U1066$2.7
AbCellera Biologics news
11.05.2022
AbCellera Biologics reported GAAP net income of $117.221 million for 3 months of 2022, down 30.5% from $168.573 million in the previous year. Revenue decreased 36% to $202.741 million from $316.581 million a year earlier.
Source: {source} pictogram investors.abcellera.com
Pictogram next
25.02.2022
AbCellera Biologics' GAAP net income for 2021 was $153.464 million, up 29.1% from $118.918 million in the prior year. Revenue increased 60.9% to $375.203 million from $233.155 million a year earlier.
Source: {source} pictogram investors.abcellera.com
Pictogram next
10.11.2021
Net income of AbCellera Biologics under GAAP for the nine months of 2021 amounted to $93.516 million, up 48.8 times from $1.917 million in the previous year. Revenues increased 9.3 times to $235.872 million from $25.247 million a year earlier.
Source: {source} pictogram investors.abcellera.com
Pictogram next
All AbCellera Biologics news
General information
Company nameAbCellera Biologics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address2215 Yukon Street Vancouver, BC V5Y 0A1 Canada
Mailing address2215 Yukon Street Vancouver, BC V5Y 0A1 Canada
Websitewww.abcellera.com
Information disclosurewww.sec.gov